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Introduction: Endothelial dysfunction is found in different pathologies such as diabetes and renal and heart
diseases, representing one of the major health problems. The reduced vasodilation of impaired endothelium starts
a prothrombotic state associated with irregular blood flow. We aimed to explore the potential of amniotic fluid
stem (AFS) cells as a source for regenerative medicine in this field; for the first time, we focused on third-trimester
amniotic fluid AFS cells and compared them with the already-described AFS cells from the second trimester.
Methods: Cells from the two trimesters were cultured, selected and expanded in normoxia (20 % oxygen) and
hypoxia (5 % oxygen). Cells were analysed to compare markers, proliferation rate and differentiation abilities.
Endothelial potential was assessed not only in vitro—Matrigel tube formation assay, acetylated human low-density
lipoprotein (AcLDL) uptake—but also in vivo (Matrigel plug with cell injection and two animal models). Specifically,
for the latter, we used established protocols to assess the involvement of AFS cells in two different mouse models
of endothelial dysfunction: (1) a chronic ischemia model with local injection of cells and (2) an electric carotid
damage where cells were systemically injected.
Results: We isolated and expanded AFS cells from third-trimester amniotic fluid samples by using CD117 as a
selection marker. Hypoxia enhanced the proliferation rate, the surface protein pattern was conserved between the
trimesters and comparable differentiation was achieved after culture in both normoxia and hypoxia. Notably, the
expression of early endothelial transcription factors and AngiomiRs was detected before and after induction. When
in vivo, AFS cells from both trimesters expanded in hypoxia were able to rescue the surface blood flow when
locally injected in mice after chronic ischemia damage, and importantly AFS cells at term of gestation possessed
enhanced ability to fix carotid artery electric damage compared with AFS cells from the second trimester.
Conclusions: To the best of our knowledge, this is the first research work that fully characterizes AFS cells from the
third trimester for regenerative medicine purposes. The results highlight how AFS cells, in particular at term of
gestation and cultured in hypoxia, can be considered a promising source of stem cells possessing significant
endothelial regenerative potential.
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Hypertension, coronary artery disease, peripheral artery
disease, and chronic renal failure are correlated with
endothelial dysfunction and a pro-inflammatory state,
the earliest events in the onset of atherosclerosis. The ef-
fects of the artery occlusion are one of the major health
problems, particularly in the adults [1] while in children
reconstruction after major oncological or vascular sur-
gery remains a difficult task. In this scenario, one of the
greatest challenges is to obtain endothelial cells from
non-vascular cell sources and researchers pay much at-
tention on the use of embryonic and fetal stem cells as
source for cell therapy. Endothelial progenitor cells de-
rived from induced pluripotent stem and embryonic
stem cells [2, 3], Wharton Jelly and umbilical cord blood
(CB) cells [2] have been recently employed to recover
the endothelial function after ischemia, but restricted
therapeutic use due to safety issues and weak differenti-
ation efficiency is limiting the applications of these cells.
A specific subset of amniotic fluid stem (AFS) cells pre-
senting the surface antigen CD117 (or c-Kit, the recep-
tor for the stem cell factor, or SCF) has been isolated,
demonstrated to be broadly multipotent [4, 5], and can
be reprogrammed without viral transduction [6]. Be-
cause of their fetal but non-embryonic origin, AFS cells
overcome many ethical concerns; moreover, they are
easy to obtain from routinely scheduled procedures dur-
ing the second trimester of pregnancy (i.e., amniocen-
tesis and amnioreduction) [7], retain immunoprivileged
properties [8] and do not form teratoma once injected
in vivo [4]. Although CD117+ cells represent about 1 %
of the initial cellular fraction of the whole amniotic fluid
(AF) [9], their specific identification and subsequent
expansion ex vivo make them a suitable candidate for
regenerative medicine. While second-trimester AF re-
quires a safe but invasive procedure during pregnancy,
third-trimester AF could be taken at birth during
cesarean sections [10]. Until now, it is not clear yet
whether AFS cells isolated by the surface marker c-Kit
could be found at term, since third-trimester AF cells
have been isolated by their adhesion properties, rather
than specific marker selection or by clonal approach
[11], showing, for instance, osteogenic potential after dif-
ferentiation in defined medium (evaluated by gene tran-
scription) [12]. Here, we focused in particular on
endothelial commitment with AFS cells from the second
and third trimesters to promote vascular repair and re-
store perfusion in ischemic tissues. Additionally, we
wanted to explore whether by culturing AFS cells in
hypoxia we could improve their culture conditions. It is
well known that stem cells normally reside in hypoxic
niches [13], so next to the usual cell cultures performed
under atmospheric oxygen tension (20 %), there are now
many protocols for cell expansion at low oxygenconcentration [14, 15]. Indeed, with particular attention
to a long-term culture, hypoxia inhibits senescence, in-
creases the proliferation rate, influences the potential of
differentiation and modulates the paracrine effects of
stem cells, causing upregulation of various secreted fac-
tors [16].
It has been demonstrated that in vivo oxygen tension
changes from the periphery to the centre of an organ,
with a lower oxygen level where stemness has to be
maintained [17]. Within this context, mimicking the nat-
ural environment, oxygen became an important factor
for in vitro stem cell expansion and potency studies. In
this study, we focused on characterizing and comparing
AFS cells from the second and third trimesters, giving
emphasis on methods of isolation and expansion, pheno-
typic profile and endothelial marker expression pattern
under normoxic and hypoxic conditions. The endothelial
commitment of AFS cells cultured in hypoxia was also
tested in vivo both in a mouse model of ischemic dam-
age and in a carotid injury model.
Methods
Samples
The samples were collected in compliance with the
Helsinki Declaration. AF samples were obtained after ap-
proval of the local ethics committee (Azienda Ospeda-
liera of Padova Pr. N. 32887/451P) by two different
gestational periods from donors who signed informed
consent. Specifically, (i) second-trimester AF samples
were collected during routine amniocentesis performed
at mid-gestation (16–18 weeks) for genetic screening
purposes. Each sample was harvested as leftover material
from amniocentesis. Only healthy samples were used. (ii)
Third-trimester AF derived from healthy women under-
going eligible cesarean section. AF from cesarean section
was unused material for clinical purposes.
Seeding and selection of AFS cells
Samples were processed in accordance with the previous
described method [18]. Briefly, cells from AFs were
seeded on glass coverslips, and adherent cells were then
positively selected for CD117 by using the MACS
CD117 MicroBead Kit from Miltenyi Biotec (Bergisch
Gladbach, Germany). Cells were cultured by using recon-
stituted Chang Medium C Lyophilized (Irvine Scientific,
Santa Ana, CA, USA) before selection and then in expan-
sion medium consisting of minimum essential medium
alpha (Gibco, now part of Thermo Fisher Scientific,
Waltham, MA, USA) containing 20 % Chang medium,
15 % fetal bovine serum (Gibco), antibiotics and L-
Glutamine (2 mM final). Cells were maintained under
standard 20 % O2, 5 % CO2 and 95 % relative humidity, re-
ferred to as “normoxia”. Cells were also cultured under
“hypoxia” at 5 % O2 by using a CO2/O2 controller
Schiavo et al. Stem Cell Research & Therapy  (2015) 6:209 Page 3 of 15connected to a hypoxic chamber (BioSpherix, Lacona, NY,
USA).
Proliferation curves and doubling time
Between 50 and 100 cells were seeded on 96-multiwell
plates, and proliferating cells were evaluated after 1, 2, 3,
6, and 9 days in culture. Cells were fixed with parafor-
maldehyde (PFA) (Sigma-Aldrich, St. Louis, MO, USA)
4 % in phosphate-buffered saline (PBS), washed in PBS
twice for 5 minutes, a brief permeabilization was carried
out with Triton X-100 0.5 % in PBS and cell nuclei were
stained with 4′,6-diamidino-2-phenylindole (DAPI)
(Sigma-Aldrich, St Louis, MO, USA). Cell numbers were
evaluated by counting the nuclei on a series of randomized
fields for the different samples and for each time point.
Flow cytometry
FACSCalibur™ and Accuri C6 (BD Biosciences, Franklin
Lakes, NJ, USA) flow cytometers were used. Acquired
data were analyzed by using FlowJo software (TreeStar
























Chicken anti-rabbit Alexafluor 488
Goat anti-mouse Alexafluor 594
Hamster anti-mouse Alexafluor 594
FITC fluorescein isothiocyanate, PE phycoerythrin, APC allophycocyanin, vWF von Wigating on viable cells. Cells analyzed starting from
freshly retrieved AF samples were filtered through
70-μm nylon mesh filter and then stained as de-
scribed above. Fresh AF and expanded AFS cells
after different passages in culture were analyzed with
antibodies listed in Table 1.
Cell cycle analysis
The staining solution consisted in PBS containing Triton
X-100 (0.1 %; Fluka,), DNAse-free RNAse A (0.2 mg/ml;
Sigma-Aldrich, St Louis, MO, USA) and propidium iod-
ide (1 mg/ml; Sigma-Aldrich, St Louis, MO, USA). After
resuspension in cold PBS and ethanol, tubes were stored
at −20 °C for at least 24 hours. After staining with
300 μl/106 cells of staining solution, cells were analyzed.
In vitro endothelial differentiation
To test the endothelial potential of AFS cells, we used the
endothelial cell tube formation assay [19] over Matrigel™
Basement Membrane Matrix (BD Biosciences, East
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llebrand factor, SSEA4 stage-specific embryonic antigen 4
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(University of Padova), were cultured in endothelial
medium (PromoCell, Heidelberg, Germany) and used just
after passage 2. AFS cells and HUVECs were detached
from the original expansion culture and seeded in EGM-2
(endothelial growth medium-2) medium (Lonza, Basel,
Switzerland) at a concentration of 15,000 cells/cm2 over
the solidified coating.
ImageJ software [20] coupled with Carpentier G.
Angiogenesis Analyzer [21] was used. For immunostain-
ings, cells were fixed with PFA 4 % in PBS and perme-
abilized with Triton X-100 0.5 % in PBS.
To test functionality [22], EGM-2 medium was re-
placed with fresh medium containing Alexa Fluor® 488
conjugated with 10 μg/ml acetylated human low-density
lipoprotein (AcLDL) (Molecular Probes, now part of
Thermo Fisher Scientific). After 6 hours, medium was
removed, and cells were fixed with PFA 4 % for later ob-
servation. Cell nuclei were counterstained with DAPI.
In vivo experiments
All the procedures involving animals and their care were
conducted in accordance with international guidelines,
with the National Institutes of Health Principles of La-
boratory Animal Care (National Institutes of Health
publication 85–23, revised 1985) and were also approved
by the local ethics committee for animal care of the Uni-
versity of Padova (organismo per il benessere degli
animali, or OPBA).
Matrigel plug
BALB/c strain Rag2−/−γc−/− immunodeficient mice
were used in order to avoid the possible cell rejection
after xenotransplant; 1 × 105 cells per plug were resus-
pended in 500 μl of Matrigel with 0.75 mg/ml hep-
arin (Pharmatex Italia, Milan, Italy), 50 ng/ml mouse
recombinant fibroblast growth factor-basic (Pepro-
Tech, Rocky Hill, NJ, USA) and 100 ng/ml human
recombinant VEGF (PeproTech). Mice were anesthe-
tized with isoflurane, and cold liquid Matrigel con-
taining cells or PBS was injected in the back lumbar
region. After 14 days, mice were euthanized and plugs
were harvested to obtain cryosections or to measure
hemoglobin (Hb).
Ischemia model
BALB/c strain Rag2−/−γc−/− immunodeficient mice
were subjected to hind-limb ischemia on the right and
left hind limbs [23]. After anesthesia with xylazine
(20 mg/kg) and ketamine (100 mg/kg) by intraperitoneal
injection, the femoral artery was excised and cauterized
from its proximal origin as a branch of the external iliac
artery to the distal point where it bifurcates into the sa-
phenous and popliteal arteries. Forty-eight hours afterischemic damage, 5 × 105 AFS cells cultured at 5 % O2
from the second (four mice) or the third (four mice) tri-
mester were injected in the adductor muscle of the right
leg while the left leg was used as control and PBS was
injected (four mice). Hind-limb microvascular perfusion
was measured with the Periscan-Pim II Laser Doppler
System (Perimed AB, Järfälla, Sweden) 15 days after sur-
gery. Specifically, Perimed proprietary software was used
to calculate the ischemic ratio by dividing the perfusion
of the ischemic limb versus the controlateral limb. For this
specific calculation, region of interest (ROI) was chosen
including each hind limb (left and right, respectively) cap-
tured by the laser Doppler image. Each ROI was equal in
size for right and left hind limbs (Additional file 1). Each
measure was repeated five times.
Electric injury model
In accordance with the procedure described in Brouchet
et al. [24], the left common carotid artery was exposed
via an anterior incision of the neck in 8-week-old BALB/
c strain Rag2−/−γc−/− immunodeficient mice (four mice
with PBS as control, four mice with AFS cells from the
second trimester and four mice with AFS cells from the
third trimester) weighting 20 g on average and under
isofluorane anesthesia. The carotid artery was injured by
electricity with a bipolar microregulator (Pfizer, New
York, NY, USA), and a 2-W discharge was applied for
2 seconds to each millimeter of carotid artery over a
total length of 4 mm with the help of a size marker
placed parallel to the long axis of the carotid. Three days
later, the endothelial regeneration process was evaluated
by staining the denuded areas with Evans blue dye as
previously described [25]. Briefly, anesthetized animals
were systemically injected via tail vein with 500 ul of 1 %
Evans blue in PBS. After 30 minutes, animals were eu-
thanized and immediately perfused with 50 ml of PBS to
remove excess of Evans blue. The left common carotid
artery was dissected and placed between slides with
mounting medium (Bioptica, Cambridge, UK). Pictures
were acquired by using a Leica DMI 6000B inverted
microscope (Leica, Wetzlar, Germany), and the ratio
between the damaged area stained in blue and the
total carotid artery area was calculated by using ImageJ
software.
Immunofluorescence
Matrigel plugs were fixed for 1–2 hours with PFA 4 % in
PBS and then dehydration was performed by sucrose
gradient method at 4 °C with sucrose 10 % in PBS for
1 hour, 15 % for 1 hour and 30 % overnight. Pieces
were then frozen in liquid nitrogen. Muscle samples
were frozen by submersion in isopentane cooled with
liquid nitrogen. Cryosections were obtained after embed-
ding samples in OCT (optimum cutting temperature)
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(Leica) to produce sections. For specific antibody concen-
trations and conditions, see Table 1. Phase-contrast and
bright-field pictures were taken by using an Olympus
IX71 inverted microscope (Olympus, Tokyo, Japan). Im-
munofluorescence pictures were acquired by using a Leica
DMI 6000B inverted microscope.
Hemoglobin quantifications
Matrigel plugs were smashed with liquid nitrogen and the
resulting powder was put in distilled water. Cell residues
were pelleted and supernatants were used for Hb quantifi-
cation by using Drabkin’s Reagent (Sigma-Aldrich). Re-
action product absorbance (or optical density) was read
at 540 nm with a SpectraMax Plus Spectrophotometer
(Molecular Devices). Hb values were normalized for the
protein content of Matrigel plugs, obtained by using
Bradford Reagent (Sigma-Aldrich) and in accordance
with the instructions of the manufacturer. Briefly, after
incubation of an aliquot of lysate (the same used for Hb
quantification) with the reagent and incubation for
30 minutes at room temperature, protein absorbance
was read at 595 nm.
Total RNA extraction and reverse transcription
Total RNA, including small non-coding RNA, was ex-
tracted by using miRNeasy Mini Kit (Qiagen, Venlo, The
Netherlands) in accordance with the instructions of the
manufacturer. RNA was quantified by using Nano-
drop2000 (Thermo Fisher Scientific), and 1 μg was ret-
rotranscribed with miScript II RT kit (Qiagen) by using
HiFlex buffer that allows the further quantification of
both mature miRNA and mRNA. All procedures were
carried out by following the instructions of the manufac-
turer and using GeneAmp® 2720 thermal cycler (Applied
Biosystems, Waltham, MA, USA).
Real-time polymerase chain reaction
For mRNA analysis, quantitative real-time polymerase
chain reaction (qPCR) was performed by using Plat-
inum® SYBR® Green qPCR SuperMix-UDG (Life Tech-
nologies, Carlsbad, CA, USA), 5 ng of cDNA and a 300
nM mix of specific forward and reverse primers (final
concentrations). For miRNA quantification, qPCR was
performed by using miScript SYBR® Green PCR KitTable 2 Primer sequences used for mRNA quantification
Gene NM_ Forward primer
ETV2 014209.2 AGTCGGACCGTGCCAGTTTG
FLI1 002017.4 *GAGGAGCTTGGGGCAATAAC
VEGF-A all isoforms TCACCATGCAGATTATGCGGA
B2M 004048.2 CAACTTCAATGTCGGATGGATG
*[28](Qiagen), 10 ng of cDNA and specific miScript Primer
Assays (Qiagen). Reactions were carried out in a Light-
Cycler II instrument (Roche, Basel, Switzerland). Results
are expressed in arbitrary units (A.U.) considering the
ratio targetRNA/referenceRNA content (reference for
mRNA: β2MICROGLOBULIN, abbreviated “B2M”; refer-
ence for miRNA: RNU6-2). For the mRNA and miRNA
primer sequence list, see Tables 2 and 3.
Statistical analysis
Data are expressed as standard error of the mean, and
statistical comparisons were performed by using Student’s
t test or one-way analysis of variance, as appropriate. Post-
hoc Bonferroni’s correction for multiple comparisons was
used. All P values of not more than 0.05 were considered
statistically significant.
Results
Antigen expression of fresh AFS cells from second and
third trimesters
The phenotypic characterization of freshly isolated cells
from both trimesters revealed high variability on the
presence of CD117+ cells, and some samples possess a
high portion of CD117+ cells and this was noticed for
both the trimesters (7.84 ± 6.50 % and 4.17 ± 3.26 % for
the second and third trimester, respectively; Fig. 1a); this
is due to the intrinsic variability among samples. In
keeping with other studies on CD117+ cells, cells from
the second or third trimester were negative for the
hematopoietic markers CD34 and CD45 and positive for
the mesenchymal molecules CD73 (5′-nucleotidase),
CD44 (a receptor for hyaluronic acid and others compo-
nents of extracellular matrices), CD105 (endoglin type I
glycoprotein), CD90 (also called Thy-1) and CD146, a
cell adhesion molecule also marking the endothelial
lineage (Fig. 1b). In particular, in the third trimester, we
detected only a small portion of CD117+ CD90+ cells
while CD117+ CD105+ cells were more abundant. This
difference in antigen expression was not detected in ex-
panded cells. The fresh CD117+ fraction did not co-
express molecules of the major histocompatibility com-
plex type II (specifically HLA-DR), whereas the major
histocompatibility complex type I (i.e., HLA-ABC) was
present. The surface antigen CD9 was markedly detected





Table 3 Qiagen primer assays used for miRNA quantification
Assay number Official symbol Qiagen catalog number Lot number
Hs_miR-126_1 MIR126 MS00003430 116330116
Hs_miR-132_1 MIR132 MS00003458 116330117
Hs_miR-210_1 MIR210 MS00003801 116330113
Hs_miR-221_1 MIR221 MS00003857 116330111
Hs_miR-222_2 MIR222 MS00007609 116330110
Hs_RNU6-2_11 N/A MS00033740 117836183
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trimester, and it was detected in almost all CD117+ cells
of the third trimester.
Characterization of AFS cells from second and third
trimesters expanded in normoxia and hypoxia
Cells yielded from third-trimester AF samples were usu-
ally higher in terms of number of cells per milliliter and
had a more heterogeneous morphology after seeding
when compared with the second trimester. However, we
were able to obtain adherent c-Kit+ colonies with cells
proliferating for several passages from cells derived from
both trimester samples in normoxic and hypoxic condi-
tions (Figs. 2a, b and 3a).
Similarly to what was observed before, the expression of
c-Kit decreased after some passages in culture [8]. Import-
antly, there were some differences between the cultured
cells, as shown in Fig. 2e. In second-trimester samples,
there was a greater percentage of cells expressing CD117
after expansion in hypoxia rather than in normoxia,
whereas third-trimester AFS cells (Fig. 2f) displayed a
similar percentage of CD117+ cells concerning the two
oxygen tensions; notably, this percentage was considerably
higher in the third than in the second-trimester cells.
Regarding other markers, as shown in Di Trapani
et al. [26], on one hand, cells were negative for the low-
affinity nerve growth factor receptor (LNGFR), referred
to as CD271, a versatile marker used to select multipo-
tent mesenchymal stem cells [27], CD31 for mature
endothelium, CD45 and CD34; on the other hand, cells
were positive for the adhesion molecules CD166 (acti-
vated leukocyte adhesion molecule, or ALCAM), CD184,
CXCR4, receptor of the stromal derived factor-1, or
SDF-1), CD146, CD29 and CD44. In addition, the spe-
cific stem cell antigen, stage-specific embryonic antigen
4 (SSEA-4), was significantly present at low oxygen in
AFS cells at term (Additional file 2).
Cell cycle (G0 and G1, S or G2 and M) was similar in-
dependently from the trimester of origin or from the
oxygen condition (Fig. 3b, left graphs) underling the
good cell division ability of both fetal cells. On the other
side, the proliferation rate was increased for cells grown
in hypoxia: after culturing at 5 % O2, significantly more
cells were obtained for both trimester samples comparedwith their counterpart cultured in normoxia (P < 0.001,
with an increase up to seven times the total number of
cells, Fig. 3b, central graphs). The estimated doubling
time came to be significantly diminished from culture at
5 % O2 in comparison with 20 % O2 (P < 0.05 for the
second trimester and P < 0.001 for the third trimester),
whereas there was no difference on the doubling time
between cells of different trimesters expanded at the
same oxygen level (Fig. 3b, right graphs). The doubling
time in normoxic environment was consistent with pre-
viously reported studies on AFS cells [4].
Cells from both trimesters were assessed for their
osteogenic and adipogenic potential. AFS cells in all condi-
tions were able to deposit calcium oxalate and to produce
lipid vacuoles when induced to differentiate respectively in
osteoblast-like and adipocyte-like cells (Additional file 3),
confirming their ability to differentiate into mesenchymal-
derived lineages.
To unravel whether AFS cells possessed a molecular
signature toward endothelial differentiation, we quanti-
fied the expression of ETV2, FLI1 and ERG1, members
of the E-twenty six transformation (ETS) family of tran-
scription factors, which direct angiogenesis and endothe-
lial progression [28] from development to post-natal life.
Notably, AFS cells at the basal state strongly expressed
ETV2, which is the earliest ETS factor to be activated.
This is consistent with their fetal origin since ETV2 is
present in endothelial precursors during development
and normally absent in adult cells (Fig. 3c, left). FLI1,
present in a more mature endothelial state, was also
expressed, although at lower levels (Fig. 3c, centre),
whereas ERG1 was not detected. Moreover, VEGF tran-
script, an important endothelial marker, was also found
in AFS cells before endothelial induction (Fig. 3c, right).
In vitro and in vivo endothelial formation
Through the Matrigel tube formation assay, we were able
to obtain successful formation of endothelial tubes mim-
icking capillary-like structures by using AFS cells from
both trimesters after expansion in 20 % or 5 % O2 (Fig. 4a).
The total area comprised in the meshes was similar in all
conditions and comparable to that of HUVECs, used as a
standard control. The branching interval was also equal
among samples and conditions, indicating uniformity of
structures and similarity in response to the endothelial
cell tube formation assay. Mesh index and mean mesh
size of AFS cells were similar to HUVECs or higher
(Fig. 4b). Capillary-like structures expressed von Willeb-
rand factor (vWF) in samples from both trimesters and
cultured at both oxygen tensions (Fig. 4c), and the endo-
thelial functionality was acquired as demonstrated by the
uptake of the lipoprotein AcLDL (Fig. 4d). In addition, we
analyzed the expression of AngiomiRs, specific miRNAs
that can promote or block the angiogenic process. In
Fig. 1 (See legend on next page.)
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Fig. 1 Cell isolation from collected amniotic fluid (from the second and third trimesters) and characterization by flow cytometry analysis. a
Representative scheme of amniotic fluid retrieval for cell extraction from second-trimester amniocentesis (upper part) and cesarean section at term
of pregnancy (below). Flow cytometry phenotyping revealed the variable presence of CD117 marker on freshly isolated cells (three-dimensional
histograms, n = 10, isotype control in gray). b Representative dot-plot cytograms showing cells from both trimesters (second trimester in orange
and third trimester in green) comparing various antigens (vertical axes) versus CD117 expression (horizontal axes)
Schiavo et al. Stem Cell Research & Therapy  (2015) 6:209 Page 8 of 15particular, miR126, 132 and 210 are key positive regula-
tors of angiogenesis and endothelial cell survival, whereas
miR221 and 222 prevent endothelial cell migration [29].
miR126, 132, 221 and 222 were detectable in AFS cells at
the basal state, whereas miR210, which was absent before
angiogenic induction (Fig. 4e), was present already after
6 hours of endothelial differentiation and decreased
72 hours after endothelial stimulation in all the analyzed
conditions. After 6, 24 and 72 hours of angiogenic induc-
tion, miR126 and 132 did not significantly change the ex-
pression level, as the anti-angiogenic miR221 and 222
were detectable in a quite stable trend.
Together with ETS factors and VEGF expression data,
these results suggest that AFS cells are transcriptionally
open for the angiogenic pathway; therefore, they may
recognize and respond to proper stimuli and undergoFig. 2 Selection, expansion of amniotic fluid stem cells and characterization
trimesters were seeded over coverslips and then selected for CD117 antige
concentrations were used for the experiments (20 % and 5 %). The obtaine
representative data for the cells obtained from the second (c) and the third
marker: red lines and numbers = normoxic condition (20 % O2); blue lines an
marker for selection (CD117) was monitored during the different passagesendothelial differentiation. Lack of markedly different
expression level between the two trimesters underlined
the endothelial imprinting of the two cell types.
To confirm their propensity to generate functional
vessels, AFS cells were also implanted in vivo, and neo-
formed and perfused vessels were detected in Matrigel
plug assay performed in immunodeficient mice (Fig. 4f ).
This macroscopic observation was further investigated
by quantifying the Hb content in plugs from each condi-
tion in comparison with the relative controls. Every sam-
ple contained significantly higher levels of Hb with
respect to controls while the optimal state was repre-
sented by the cells cultured in hypoxia (Fig. 4f, graph).
In all of the different culture conditions, some vWF-
expressing structures were also positive for the human
mitochondria antigen (Fig. 4g) with the exception ofof obtained cultures. a, b Cells contained in amniotic fluid of both
n for subsequent expansion in culture, and two different oxygen
d cells were then characterized for surface markers; here are
(d) trimester with their percentage of positive cells for each specific
d numbers = hypoxic condition (5 % O2). The presence of the initial
in culture for second-trimester (e) and third-trimester (f) cells
Fig. 3 AFS cell morphology and behavior in culture. a AFS cells from both trimesters were expanded in normoxic (20 % O2) or hypoxic (5 % O2)
conditions maintaining sub-confluence between passages (scale bar = 200 μm). b For each type of sample and culture condition, the cell cycle
phases (G0-G1, S and G2-M) were quantified by flow cytometry after propidium iodide staining of the cells (left graphs). Cells in well were counted
at different time points to obtain a growth curve (central graphs) and were expressed by population doublings at each measured point (n = 5). From
the growth curve, the mean doubling time (right graphs) for each condition was calculated and compared to see whether hypoxia was influencing
the time window of cell replication. c Endothelial transcription factor detection: ETV2, FLI1 and VEGFA were expressed at basal level in AFS cells. *P <
0.05, ***P < 0.001. CB was used as positive control for ETV2 expression, whereas the adult HUVECs were used as positive control for the other two
genes (white bars); 20 % O2 condition represented by red bars and lines; 5 % O2 condition represented by blue bars and lines. AFS amniotic fluid stem,
A.U. arbitrary units, CB cord blood, HUVEC human umbilical vein endothelial cell
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endothelial marker.
Second- and third-trimester AFS cells regenerate
damaged endothelium in vivo
To prove whether endothelium derived from AFS cells
could function, two distinct animal models were used to
mimic endothelial dysfunctions: ischemic damage after
femoral excision and carotid injury. Cells cultured in
hypoxia were chosen because of their superior capacity
to proliferate.
After the femoral artery excision, Doppler analysis evi-
denced how the superficial blood circulation was signifi-
cantly ameliorated in cell-treated mice compared with
PBS-injected muscles (Fig. 5b); an increased number of
CD31+ capillaries was also observed in treated mice
(double staining for anti-human and anti-murine CD31
was negative; data not shown). Although the difference
in terms of CD31+ cells between PBS- and cell-injected
muscles was not significant, the positive trend was no-
ticeable after treatment with both second- and third-
trimester AFS cells (Fig. 5c). By immunofluorescence
for human antigens such as human Nuclei, anti-humanMitochondria and Lamin A/C, we tried to identify and
confirm the participation of injected AFS cells in sup-
porting angiogenesis and vascular regeneration in
muscle, but very rare cells were found and no coexpres-
sion of endothelial marker was evident. Also, reverse
transcription-PCR for human BM2 was performed
without positive results (data not shown). Conse-
quently, the endothelial recovery was postulated as out-
come of a bystander effect. To study the indirect
mechanism of endothelial reconstitution, a mouse
model of electric carotid artery injury was subsequently
used (Fig. 5d). After Evans blue injection, the impaired
endothelium of control mice absorbed the blue staining
while cell-treated animals underwent almost complete
endothelial restoration 3 days after electric injury, as
demonstrated by the very small presence of Evans blue-
positive areas (Fig. 3e). In particular, AFS cells from the
third trimester proved to be more effective than AFS
cells from the second trimester in repairing the dam-
aged artery. Given the endothelial wall of the cell-
injected mice, it was clear how the shape was regained
when compared with the loose endothelial wall of the
PBS-treated animals.
Fig. 4 (See legend on next page.)
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Fig. 4 In vitro and in vivo endothelial differentiation and miR expression of AFS cells. a AFS cells were seeded over Matrigel-coated wells, and
phase-contrast images showed network formation after 24 hours (scale bar = 100 μm). Image analysis of those network structures (b) produced
values that were compared against standard positive control cells (HUVECs, left white bars), and statistical significance is shown among AFS cells
and control with asterisks, also between different concentrations of oxygen for the same trimester with hashes (n = 10). Immunofluorescence
stainings of endothelial network (c) showed vWF (green signal) expression (scale bar = 100 μm). d Ability of endothelial cells to intake AcLDL:
green vesicles are indicated by white arrows, phase contrast (left) and fluorescence detection (right) are shown for better appreciation (scale bar
= 200 μm). *P < 0.05, **P < 0.01, ***P < 0.001 #P < 0.05, ###P < 0.001. e Time course of pro angiomiR (miR126, 132 and 210) and anti angiomiR
(miR221 and 222) expression after differentiation. f Upper row: Matrigel plugs (n = 3 for each condition. Experiment # = experiment number)
underwent hemoglobin (Hb) test: relative quantification of Hb was higher in plugs loaded with AFS cells cultured at 5 %. Lower row: appearance
of the harvested plugs with and without cells before Hb quantification. g Representative expression of vWF (green signal) co-localized with a
specific human antigen (human mitochondria, red signal) (scale bar = 50 μm). All nuclei in the figure were counterstained with DAPI. AcLDL acetylated-low
density lipoprotein, AFS amniotic fluid stem, A.U. arbitrary units, CB cord blood, DAPI 4′,6-diamidino-2-phenylindole, HUVEC human umbilical vein endothelial
cell, PBS phosphate-buffered saline, PhC phase contrast, vWF von Willebrand factor
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In the present study, we compared the features of AFS
cells from the third trimester with the ones of the well-
defined second-trimester AFS cells. Specifically, we
aimed to assess both in vitro and in vivo the differenti-
ation potential toward endothelial lineage of third-
trimester AFS cells under hypoxic conditions. Cells de-
rived from AF at term have only recently been consid-
ered as an alternative source of stem cells [12, 30], and
in particular this is the first study that looks at the c-Kit
+ population derived at term for endothelial regener-
ation. The antigen profile gains in importance on the
definition of both stemness and immunological proper-
ties. The latter has been recently addressed, showing that
AFS cells from the second and third trimesters inhibit T
and natural killer cells in a similar manner [26]. The evi-
dent overlapping of the characteristics of the two trimes-
ter sources has major implications since AFS cells from
the last trimester of gestation are an easily available and
abundant source without ethical concerns mainly be-
cause they are discarded material. It is possible that
stemness maintenance during gestation is related to the
low oxygen tension in the AF since oxygen concentra-
tion is a key element of both cell proliferation and differ-
entiation [31]. In this regard, without the addition of
synthetic chemicals and coating, 5 % oxygen turned out
to be sufficient to halve the doubling time and to keep
mostly unchanged both the phenotype and the differen-
tiation ability in respect to 20 % of oxygen. For the latest
point, our method of culture turned out to be of para-
mount importance: contrary to other researchers [32],
we were able to confirm the endothelial differentiation
comparable to HUVECs.
It is known that angiogenesis is a process starting from
pre-existing vasculature and the first elements involved
are endothelial cells that must activate to undergo prolif-
eration, allowing the formation of new vessels. In our
plug assay, AFS cells were able to switch from a stem to
a more committed state and to build a functional endo-
thelial network. In addition, the vessel formation insidethe plug has been proven to be of human origin, further
confirming that our cells actively contributed to the
endothelial network.
Specific ETS transcription factors essential for angio-
genic differentiation and vessel formation [28] are con-
stitutively expressed by endothelial precursor cells.
Following the work of Ginsberg et al., we focused our
analysis on ETV2, present specifically in fetal endothelial
precursors, FLI1 and ERG1, detected in adult endothelial
progenitor cells. Ginsberg et al. demonstrated how the
insertion of the abovementioned genes in AF cells, de-
pleted of c-Kit+ population, were able to easily convert
AF cells into endothelial progenitor cells. Our results
highlighted how c-Kit+ AFS cells are already transcrip-
tionally open toward endothelial differentiation without
the need of any genetic manipulation. ETV2, a marker of
fetal endothelial precursor cells, was more present in
AFS cells than in the CB cells used as control, whereas
FLI1 was detected at a lower level in respect to the con-
trol (HUVECs). This agrees both with the fetal origin of
AFS cells and with their stemness state, but these cells
also display an open state toward mature endothelium
formation. It is possible that microRNAs (miRNAs) have
a role in the post-trascriptional regulation of those genes
[33, 34]. Specifically, we chose to look into the expres-
sion of miR126, 132 and 210, which promote angiogen-
esis by targeting negative regulators in angiogenic
pathways. Endothelial cell-specific miR126 plays an es-
sential role in neoangiogenesis following ischemia [35]
and was detected in AFS cells before endothelial induc-
tion and maintained during differentiation. Importantly,
the expression of miR210, which is a key regulator of
angiogenesis [36], rapidly increased after induction. In
addition, we focused on the anti-angiomiR221 and 222
[37], which inhibit the process of angiogenesis by de-
grading positive regulators. It has been demonstrated
how these two miRNAs regulate the angiogenic activity
of SCF and the level of its receptor c-Kit [38]. Our study
underlines how AFS cells express also these anti-
angiomiRs in the basal condition as if AFS cells could be
Fig. 5 (See legend on next page.)
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Fig. 5 Endothelial rescue after AFS cell injection in vivo. a Experimental plan. Mouse model of acute ischemia: 48 hours after bilateral femoral
vein excision, PBS or AFS cells from the second and third trimesters were injected. Fifteen days later, functional analysis and sacrifice have been
performed. b In comparison of mice injected with PBS (control) and of those treated with cells, the ischemic ratio was significantly higher in the
latter group (n = 4 for each condition). ROI used to calculate the ischemic ratio was equal in size for right and left limbs. c CD31 staining of cells
in both control and treated animals (left) evidenced a positive trend in favour of the cell-treated mice but with no statistical differences (right)
(n = 5 for each condition). d Experimental plan. Mouse model of carotid injury: 3 hours after damage, PBS or AFS cells cultured in hypoxia were
injected. e Three days later, after Evans blue injection, it is possible to appreciate the quick recovery of the damaged endothelium after AFS cell
injection. In particular, AFS cells of the third trimester proved to be significantly more effective than the cells from the second trimester (n = 3 for
each condition). *P < 0.05, ***P < 0.001. AFS amniotic fluid stem, DAPI 4′,6-diamidino-2-phenylindole, PBS phosphate-buffered saline, PhC
phase contrast
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endothelial differentiation. Overall, our in vitro results
showed that AFS cells of the second and third trimesters
both possess the gene expression profile for an efficient
endothelial differentiation not only on the transcription
factors side but also because the post-transcriptional
modulators of angiogenic gene detection were revealed.
Indeed it was evident that, although anti-angiomiRNA
expression was maintained, cells in vitro were prone to
differentiate toward endothelium, highlighting the ability
to selectively receive and enhance the pro-angiogenic
stimuli.
Different sources of mesenchymal stem cells of fetal
and adult origin, from CB to adipose-derived cells or
embryonic stem cells, have been shown to contribute to
endothelial regeneration but the functionality of these
cells has been only partially proven in vivo [2, 39–41] or
are difficult to expand in culture [42]. In the well-
established mouse model of ischemia used here, the cells
were injected 48 hours after resection of both femoral
arteries. In such a harsh microenvironment, the action
of AFS cells of both trimesters was consistent and ro-
bust. They were indeed capable of ameliorating the
blood flow as highlighted by Doppler analysis, although
AFS cells were not detectable. This phenomenon is in
keeping with previous literature describing that AFS
cells exert an indirect effect through a paracrine action
as demonstrated in the repair of intestine, kidney, lung
and heart [43–46] and in a different model of endothe-
lial damage [47]. In this ischemia model, AFS cells exert
a bystander effect, but to deeply investigate this aspect
toward endothelial regeneration, we decided to use a dif-
ferent animal model always based on artery damage.
This specific model, defined by Carmeliet et al. [48] in
the femoral artery and adapted by Brouchet et al. [24]
for the carotid damage, well represents a model of indir-
ect endothelial repair. Indeed, Hagensen et al. [49] inves-
tigated the mechanism of endothelial reconstitution,
demonstrating how the model of carotid impairment it-
self regenerates spontaneously from the distal part to the
centre of the damaged area. In particular, injured carotid
from wild-type mouse transplanted into GFP animal
proved how the activation of the resident healthyendothelium (GFP+ cells) toward the damaged area was
the mechanism of the endothelium-restauration, giving
up the theory that circulating endothelial progenitors
cells could contribute themselves to de novo endothelial
cells [50]. However, when bone marrow or endothelial
cells are injected in the same mouse model, the ability to
re-build the artery wall has been demonstrated to be su-
perior and quicker [51, 52]. For these experimental rea-
sons, we decided to perform AFS cell injection in
damaged carotid, believing that cell contribution could
improve the endothelial healing via the bystander effect.
Indeed, 3 days after damage, the reduced area with
Evans blue staining confirmed the attained regeneration.
Given that this model regenerates spontaneously in
10 days [49], the synergy between AFS cells and the resi-
dent endothelium was clear since in control animals no
endothelial restoring was seen after 3 days. In addition,
we can appreciate the stronger ability of endothelial re-
covery of our cells with respect to HUVECs or bone
marrow cells [51].
Conclusions
In this work, we compared the features and the endothe-
lial properties of AFS cells from two trimesters, charac-
terized mainly by different accessibility and abundance.
AFS cells from the third trimester, which have the ad-
vantage of being available from healthy fetuses of sched-
uled cesarean section, proved to possess comparable
properties with respect to AFS cells from the earlier tri-
mester but were characterized by a quicker proliferation
rate when cultured in hypoxia. AFS cells of both trimes-
ters were able to differentiate both in vitro and in vivo
into endothelial cells and, in two different disease
models, did sustain residing endothelial precursor cells
to rescue tissue function, with the third-trimester cells
demonstrating a stronger action in the carotid mouse
model.
This is the first study that deeply characterizes the
third-trimester AFS cells and investigates them as a new
source for potential therapeutic applications. In the fu-
ture, ex vivo engineering of endothelial structure using
AFS cells will completely address the differentiation po-
tential of AFS cells that so far did not directly generate
Schiavo et al. Stem Cell Research & Therapy  (2015) 6:209 Page 14 of 15new endothelium. Comparison of endothelial cells de-
rived by direct differentiation or reprogramming could
become necessary in order to decide the most efficient
and safe method for their clinical use.
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(left images) (scale bar = 200 μm) and relative quantification (right graph)
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21 of differentiation. (B) Osteogenic differentiation was attained and
calcium salt accumulation was detected by Von Kossa staining (top left
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from differentiating cells were also extracted and quantified at different
time points (top right graph) (n = 3). Alkaline phosphatase activity was
observed by colorimetric substrate modification (bottom left images) on
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